menu
    • menu
    [{"orgOrder":0,"company":"Berg Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Berg Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Undisclosed"},{"orgOrder":0,"company":"Berg Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Berg Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Undisclosed"},{"orgOrder":0,"company":"Berg Health","sponsor":"BPGbio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Berg Health \/ Berg Health","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Berg Health"},{"orgOrder":0,"company":"Berg Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Berg Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Undisclosed"},{"orgOrder":0,"company":"Berg Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Berg Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Undisclosed"},{"orgOrder":0,"company":"Berg Health","sponsor":"AdventHealth","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Collaboration","leadProduct":"Ubidecarenone","moa":"aldosterone antagonists (spironolactone type)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Berg Health \/ AdventHealth","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ AdventHealth"}]

    Find Clinical Drug Pipeline Developments & Deals by Berg Health

    Menu

    Berg Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : BPGbio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme

                            Details : BPM 31510, the company’s lead drug candidate, acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 06, 2023

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : BPGbio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BERG to Present Phase 1 Results of BPM 31510-IV and Identifies Therapeutic Opportunities for Recurrent GBM Pat...

                            Details : Abstract titled "Comprehensive molecular pharmacodynamic assessment identifies response markers of intermediary metabolism associated with BPM31510-IV treatment in advanced glioblastoma multiforme patients" will be presented at the ASCO meeting.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 02, 2021

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BERG To Conduct Phase Two Trial For Treatment Of Deadly Glioblastoma Multiforme [GBM]

                            Details : Preclinical evidence in an aggressive orthotopic model of GBM suggests that pre-treatment (priming) followed by co-administration of BPM31510 in combination with standard of care, such as radiation and chemotherapy, led to an increase overall survival ra...

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            March 22, 2021

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : AdventHealth

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BERG Deepens Research Collaboration With AdventHealth To Advance Aging, Metabolism and Nash Research

                            Details : The partnership is comprised of separate investigations that employ BERG’s Interrogative Biology® platform to examine potential biomarker signatures of age-related disease. This also includes Phase II trial of BPM31510 on platelet and skeletal muscle ...

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            December 15, 2020

                            Lead Product(s) : Ubidecarenone

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : AdventHealth

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BERG To Present Discovery/Validation Of Biomarkers Associated With Survival In Pancreatic Ductal Adenocarcinom...

                            Details : BPM 31510-IV (ubidecarenone) also known as coenzyme Q10 used in advanced refractory pancreatic ductal adenocarcinoma and identified two potential biomarkers overall survival and progressive disease.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            September 18, 2020

                            Lead Product(s) : Ubidecarenone,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer T...

                            Details : Initial results showed efficacy in patient's refractory to chemotherapy regimens and identification of potential biomarkers of survival guided by the use of the BERG Interrogative Biology® platform.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 27, 2020

                            Lead Product(s) : Ubidecarenone,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth